Juan D Cañete

Feb 15, 2024 | nature.com | Juan D Cañete |Jaume Bacardit

Current treatments for rheumatoid arthritis aim to achieve and maintain disease remission, which is characterized by the absence of symptoms of inflammation1. However, remission is often fragile, with about 50% of patients experiencing disease flares after reducing or stopping medication, representing a burden for both patients and clinicians1. Although some predictors of flare exist, they do not confidently predict flare for most patients with rheumatoid arthritis in remission2.